Gilead Sciences, Inc. (GILD) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Gilead Sciences, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes medicines for diseases including HIV, hepatitis B and C, and certain cancers. The company operates globally with research, manufacturing, and distribution facilities across multiple continents to serve patients worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, GILD is trading at more than a 25% premium to estimated fair value.

GILD currently ranks #104 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $151.00
Sector: Healthcare
12-month range: $119.79–$150.03

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Overbought
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for GILD

Our model validated 16 trailing price-to-earnings windows for GILD, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $119.79–$150.03.
The 14-day relative strength index sits at an overbought 75.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for GILD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent GILD news

TickrTrends' derived news-sentiment signal for GILD is currently leaning positive, computed from recent coverage.

Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? (insidermonkey.com, 2026-09-08)
TickrTrends take: Gilead's Bixlenvo approval opens a new revenue opportunity in HIV treatment, which could support revenue growth in a mature therapeutic area where the company faces patent expirations and competitive pressures. Given TickrTrends' current overvalued assessment, investors monitoring the company's valuation should track whether this product's uptake and market penetration justify current pricing, particularly as the healthcare sector faces ongoing pricing scrutiny. The actual addressable market size and Bixlenvo's ability to capture share from existing treatments will be critical data points for reassessing whether the company's valuation multiple reflects realistic growth prospects.
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? (finance.yahoo.com, 2026-09-05)
TickrTrends take: Gilead Sciences has secured multiple FDA approvals within a compressed timeframe, demonstrating accelerating clinical success that could drive future revenue growth. However, TickrTrends currently rates the stock as overvalued, suggesting that recent approvals may already be reflected in the current share price. A valuation-focused investor should monitor whether the company can convert these regulatory wins into earnings growth sufficient to justify current valuations in the competitive Healthcare sector.
Is Gilead Sciences Stock Outperforming the S&P 500? (finance.yahoo.com, 2026-09-03)
TickrTrends take: Gilead Sciences operates in the Healthcare sector and currently carries an Overvalued designation according to TickrTrends analysis. Questions about stock performance relative to the S&P 500 warrant consideration alongside the company's current valuation metrics, as near-term outperformance does not necessarily reflect underlying value positioning. Investors focused on valuation should monitor whether relative strength coincides with any compression in the overvaluation gap or if the stock continues to trade at a premium to justified levels.

What people are saying

Follow the GILD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — GILD's technical positioning has shifted this week with several notable changes in TickrTrends' derived indicators. The stock's momentum rating has been removed from its previous B grade, while the RSI zone has moved from neutral into overbought territory, suggesting potential near-term pullback risk. Additionally, GILD's sector discount rank has declined from number 99 to number 104 among Healthcare stocks, indicating it is trading with less of a discount relative to its peers, which aligns with the current overvalued verdict.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is GILD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), GILD is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is GILD's TickrTrends verdict?

GILD's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does GILD compare to other Healthcare stocks?

GILD ranks #104 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is GILD overbought or oversold?

GILD's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

GILD vs ACAD · GILD vs ALKS · GILD vs AMGN · GILD vs BMY · GILD vs CDNA